F S&P 500
5,044.25 -3.25 (-0.06%) F Dow Jones
38,461.00 -7.00 (-0.02%) F Nasdaq
17,325.50 -24.50 (-0.14%) E-mini Russell 2000 Index Futur
1,981.00 -1.60 (-0.08%) Petróleo
83.02 +0.17 (+0.21%) Oro
2,320.90 -25.50 (-1.09%)
Syndax Pharmaceuticals, Inc. (SNDX)
Fuera de horario:
Syndax Pharmaceuticals, Inc.
35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400
https://www.syndax.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 184
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael A. Metzger M.B.A. | CEO & Director | 1.1M | 126.68k | 1971 |
| Dr. Neil Gallagher M.D., Ph.D. | President, Head of Research & Development | 720.46k | N/D | 1964 |
| Mr. Keith Alan Goldan CPA | CFO, Treasurer & Chief Accounting Officer | 674.65k | N/D | 1971 |
| Mr. Luke J. Albrecht | Senior VP, General Counsel & Secretary | 631.36k | 387.36k | 1979 |
| Dr. Catherine Madigan M.D. | Chief Medical Officer | 655.84k | N/D | 1972 |
| Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer | N/D | N/D | 1969 |
| Dr. Richard A. Heyman Ph.D. | Co-Founder | N/D | N/D | 1957 |
| Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board | N/D | N/D | 1949 |
| Dr. Michael Downes Ph.D. | Co-Founder | N/D | N/D | N/D |
| Sharon Klahre | Vice President of Investor Relations & Communications | N/D | N/D | N/D |
Descripción
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Syndax Pharmaceuticals, Inc. a partir del 1 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 8; Derechos del accionista: 8; Compensación: 7.
